Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies

Ulrich Ebensperger

Financial Analyst
 
share with twitter share with LinkedIn share with facebook
share via e-mail

An opportunity over the medium term?

Strategy published on 11/08/2016 | 08:59
long trade
Live
Entry price : 224.9CHF | Target : 280CHF | Stop-loss : 218CHF | Potential : 24.5%
Roche Holding Ltd. shares have returned to important technical levels around 220.1 CHF based on weekly price data. The timing seems attractive to be a buyer of this stock.
Investors have an opportunity to buy the stock and target the CHF 280.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's earnings releases usually do not meet expectations.
  • With an enterprise value anticipated at 4.04 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ROCHE HOLDING LTD.3.40%211 657
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
MERCK AND COMPANY-6.96%155 214
AMGEN19.97%128 762
SANOFI-4.32%111 499
NOVO NORDISK A/S29.49%105 152
BAYER5.62%104 029
BRISTOL-MYERS SQUIBB COMPAN..6.81%103 881
ELI LILLY AND COMPANY17.54%96 775
ABBOTT LABORATORIES42.38%95 837
GLAXOSMITHKLINE-17.57%86 798
CELGENE CORPORATION-8.35%85 188
ASTRAZENECA9.90%83 019
ALLERGAN PLC-20.10%56 286
More Results
Financials ( CHF)
Sales 2017 53 500 M
EBIT 2017 18 164 M
Net income 2017 10 965 M
Debt 2017 10 098 M
Yield 2017 3,56%
P/E ratio 2017 18,18
P/E ratio 2018 16,67
EV / Sales 2017 4,10x
EV / Sales 2018 3,86x
Capitalization 209 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ROCHE HOLDING LTD.
Duration : Period : Day
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Duration : Period : Week
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders